Biogen Drug Wins Accelerated FDA Nod for Treating Rare Genetic Form of ALS
The Biogen amyotrophic lateral sclerosis drug, Qalsody, treats patients whose disease is driven by mutations to a gene called SOD1. It’s the first drug approved to target a genetic cause of ALS.